The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.
In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:
- Investment banks, venture capital and private equity firms, royalty monetization firms, private investment and hedge funds, and individual investors focused on funding life sciences-related companies
- Food, dietary supplement, cosmetics and consumer product companies
- Academic medical centers and research institutions
- Veterinary, agricultural and industrial applications
Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:
Ropes & Gray’s life sciences team has handled every type of transaction from licensing agreements with a small biotechnology company to large mergers of industry-leading pharmaceutical and medical device companies around the globe. Recent noteworthy transactions include representation of:
- Pfizer on its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
- Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
- Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
- Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
- Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic. As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
- Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, in its $65 million definitive license agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18.
- Zai Lab in its $30 million Series C preferred equity financing round, led by OrbiMed with other new investors Vivo Capital, Cormorant and Rock Springs Capital.
- Mersana Therapeutics, a clinical-stage biopharmaceutical company, in connection with its $75 million initial public offering.
- A leading pharmaceutical company in a patent case involving the use of Botox® to treat pain from spinal compression, where the representation included a trial before the PTAB.
- Bain Capital Life Sciences in its $70 million convertible preferred PIPE investment in Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics.